Cryptococcus neoformans is an encapsulated yeast responsible for approximately a quarter
of a million deaths worldwide annually despite therapy, and upwards of 11% of HIV/AIDS …

Cryptococcal meningoencephalitis is an urgent global health problem. Induction regimens
using 14 days of amphotericin B deoxycholate (dAmB) are considered the standard of care …

We evaluated the antifungal activities of amphotericin B, fluconazole, and flucytosine, alone
and in combination, in a murine model of cryptococcal meningitis. The objectives were to …

As the oldest and for many decades the only available agent for the treatment of life-
threatening invasive fungal diseases, amphotericin B (AmB) is known for its broad-spectrum …

Cryptococcal Meningitis (CM) is uniformly fatal if not treated, and treatment options are
limited. We previously reported on the activity of APX2096, the prodrug of the novel Gwt1 …

Cryptococcal meningitis was induced in BALB/c mice by intracerebral infection with
Cryptococcus neoformans. Drug therapy was initiated 1 day later, with mice receiving …

Studies with animals and in vitro studies have demonstrated that flucytosine plus
amphotericin B or fluconazole has significantly improved mycologic activity against …

To assess the possible beneficial effects of combined therapy (fluconazole and flucytosine)
in the treatment of cryptococcal meningitis in the immunocompromised host, we compared …

This study elucidates the role of combined fluconazole and flucytosine as therapy for
cryptococcosis in the murine model of meningitis. Three strains of Cryptococcus neoformans …

We measured fungicidal activity of continuous infusion of amphotericin B deoxycholate plus
5 ″flucytosine using quantitative cultures of cerebrospinal fluid (CSF) obtained from lumbar …